期刊文献+

大剂量甲氨蝶呤在成人急性淋巴细胞白血病中的应用及研究进展 被引量:14

Application and research progress of high-dose methotrexate in adult acute lymphoblastic leukemia
原文传递
导出
摘要 急性淋巴细胞白血病是一种高度异质性疾病。甲氨蝶呤(MTX)是治疗儿童及成人急性淋巴细胞白血病的常用化疗药物,大剂量甲氨蝶呤逐渐代替头颅放疗成为预防中枢神经系统复发及治疗的主要措施,大大提高了患者的无事件生存率和总生存率。大剂量MTX的不良反应主要有肝、肾功能损害,骨髓抑制,口腔黏膜炎等,亚叶酸钙作为大剂量MTX特异性解毒药物可以对抗其细胞毒效应。 Acute lymphoblastic leukemia (ALL) is methotrexate (MTX) is the common chemotherapy in treating place of cranial radiotherapy and becomes the main measure nervous system relapse. That greatly improves the event- free a highly heterogeneous disease. High- dose children and adults ALL. It gradually takes the of the prophylaxis and treatment in the central survival (EFS) and overall survival (OS) of patients. The main adverse reactions of high-dose MTX are liver and kidney damage, bone marrow suppression, oral mucositis, and so on. Leucovorin is the high-dose MTX specific antidote which can reduce cytotoxic effects of high-dose MTX.
作者 陈丽娜 华建媛 郑积富 石庆之 CHEN Li-na HUA Jian-yuan ZHENG Ji-fu SHI Qing-zhi(Department of Hematology, the Second Affiliated Hospital of Nanchang University, Nanchang JIANGX1 330006, China Key Laboratory of Experimental Hematology, Nanchang JIANGXI 330006, China School of Medicine, Graduate School of Nanchang University, Nanchang JIANGXI 330006, China)
出处 《中国新药与临床杂志》 CAS CSCD 北大核心 2017年第1期7-10,共4页 Chinese Journal of New Drugs and Clinical Remedies
基金 江西省卫生计生委科技计划(20155331) 江西省科技支撑计划项目(20151BBG70169)
关键词 甲氨蝶呤 白血病 淋巴细胞 急性 亚叶酸钙 药物毒性 methotrexate leukemia, lymphoblastic, acute calcium folinate drug toxicity
  • 相关文献

参考文献7

二级参考文献77

  • 1杨丽华,卢新天,卢炜,华瑛,赵卫红,卢薇薇.淋巴系恶性肿瘤患儿大剂量氨甲蝶呤剂量个体化的临床研究[J].临床儿科杂志,2006,24(2):104-106. 被引量:6
  • 2顾龙君.儿童急性淋巴细胞白血病诊疗建议(第三次修订草案)[J].中华儿科杂志,2006,44(5):392-395. 被引量:476
  • 3Nachman J, Sather HN, Cherlow JM, et al. Response of children with high-risk acute lymphoblastic leukemia treated with and without cranial irradiation: a report from the Children's Cancer Group. J Clin Oncol, 1998, 16:920-930.
  • 4Pui CH, Campana D, Pei DQ. Treatment of childhood acute lymphoblastic leukemia without prophylactic cranial irradiation. N Fngl J Med, 2009, 360: 2730-2741.
  • 5Evans WE, Crom WR, Stewart CF, et al. Methotrexate systemic clearance influences probability of relapse in children with standard-risk lymphoeytie leukemia, l,ancet, 1984,1:359-362.
  • 6Buhrer C, Henze G, Hofmann J, et al. Central nervous system relapse prevention in 1165 standard:risk children v6th acute lymphoblastic leukemia in five BFM trials. Haematol Blood Transfus, 1990,33: 500-503.
  • 7Reiter A, Sehmppe M, l,udwig WD, et al. Chemotherapy in 998 unselected childhood acute lymphoblastie leukemia patients. Results anti conclusions of lhe muhicenter trial ALI,-BFM 86. Blood, 1994, 84:3122-3133.
  • 8Schrappe M, Reiter A, Ludwig WD, et al. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. German-Austrian-Swiss ALI,-BFM Study Group. Blood, 2000, 95 :3310-3322.
  • 9Moricke A, Reiter A, Zimmermann M, et al. Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial AI,L-BFM 95. Blood, 2008, 11 1:4477-4489.
  • 10Matloub Y, Lindemulder S, Gaynon PS, et al. lntrathecal triple therapy decreases central nervous system relapse but fails to improve event-free survival when compared to intrathecal methotrexate: results off the Children's Cancer Group (CCG) 1952 study for standal-risk acute tymphoblastic leukemia. A report from the Children's Onc01ogy Group. Blood, 2006, 108 : 1165-1173.

共引文献199

同被引文献114

引证文献14

二级引证文献56

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部